All In Biotech

Drug Trial Radar · NCT06142175

Relmacabtagene Autoleucel in Patients With LBCL

A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 28, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

Conditions

  • Large B-cell Lymphoma

Interventions

  • Relmacabtagene AutoleucelBiological

    A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.